Avalo Therapeutics
AVTX
19 hedge funds and large institutions have $28M invested in Avalo Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
52% more capital invested
Capital invested by funds: $18.4M → $28M (+$9.56M)
6% more funds holding
Funds holding: 18 → 19 (+1)
0% more ownership
Funds ownership: 0.25% → 0.25% (+0%)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$102K |
| 2 |
Morgan Stanley
New York
|
+$5.21K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$43K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$39.1K |
| 3 |
Goldman Sachs
New York
|
-$14.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.61K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$2.38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
26
Parallel Advisors
San Francisco,
California
| $5 | – | – | – |
|
|
27
BNP Paribas Financial Markets
Paris,
France
| – | -$2.38K | -3 | Closed |
|
AVTX Hedge Fund Activity: Q4 2022 in Review
19 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2022, worth a combined $28M — up 52% from $18.4M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AVTX positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $102K. The largest seller was Millennium Management, cutting an estimated $43K.
- 19 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2022, up from 18 in Q3 2022.
- Funds reported $28M of Avalo Therapeutics stock for Q4 2022, up 52% quarter-over-quarter.
- 2 funds opened new Avalo Therapeutics positions in Q4 2022 and 1 closed out, a net change of +1 holder.
- The largest Avalo Therapeutics buyer in Q4 2022 was Susquehanna International Group, an estimated $102K added.
- The largest Avalo Therapeutics seller in Q4 2022 was Millennium Management, an estimated $43K sold.
Based on aggregated 13F filings for Q4 2022.